HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
libenzapril
structure given in first source
Also Known As:
CGS 16617; CGS-16617; 1H-1-Benzazepine-1-acetic acid, 3-((5-amino-1-carboxypentyl)amino)-2,3,4,5-tetrahydro-2-oxo-
Networked:
5
relevant articles (
0
outcomes,
1
trials/studies)
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Benzazepines: 5
libenzapril: 5
Related Diseases
1.
Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
01/01/1988 - "
Effects of two nonsulfhydryl angiotensin-converting enzyme inhibitors, CGS 14831 and CGS 16617, on myocardial damage and left-ventricular hypertrophy following coronary artery occlusion in the rat.
"
01/01/1988 - "
The present study was designed to examine the effects of two new angiotensin-converting enzyme (ACE) inhibitors, CGS 14831 and CGS 16617 (3 mg/kg i. v. 1 min prior to occlusion and 4 and 24 h after occlusion), on myocardial ischemic (MI) damage and left-ventricular hypertrophy in rats.
"
2.
Hypertension (High Blood Pressure)
01/01/1993 - "
A previous communication from this laboratory reported that brain uptake of libenzapril, a small polar molecule, was enhanced in chronic hypertension (1).
"
02/01/1992 - "
Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril.
"
3.
Hemorrhagic Shock
07/01/1987 - "
The effect of a specific inhibitor of thromboxane (Tx) A2 synthesis, CGS-13080, a new angiotensin converting enzyme inhibitor, CGS-16617, and a combination of both drugs was studied in hemorrhagic shock in rats.
"
4.
Shock
07/01/1987 - "
CGS-16617 (1 microgram/kg) attenuated significantly the pressor response to angiotensin I throughout the shock period.
"
5.
Myocardial Infarction
07/01/1987 - "
A specific inhibitor of thromboxane A2 (TxA2) synthesis, CGS-12970, a new angiotensin-converting enzyme (ACE) inhibitor, CGS-16617, and a combination of both agents were evaluated for their ability to reduce the extension of myocardial infarct size in rats.
"
Related Drugs and Biologics
1.
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
2.
Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
3.
benazeprilat
4.
Thromboxanes
5.
Thromboxane A2 (A2, Thromboxane)
6.
Cathepsin D
7.
Angiotensin I
8.
3-methyl-2-(3-pyridyl)-1-indoleoctanoic acid
9.
pirmagrel